287
Participants
Start Date
June 27, 2019
Primary Completion Date
September 29, 2025
Study Completion Date
September 29, 2025
cemiplimab
No investigational agents will be provided to enrolled patients by the sponsor as part of this study. Patients will have recently initiated or be planning to initiate treatment with commercially available cemiplimab for advanced CSCC or advanced BCC in a real-world setting according to respective label indications. In addition to cemiplimab, patients may receive other therapies as deemed necessary by their physicians for the treatment of CSCC or BCC or comorbid conditions.
Regeneron Research Facility, New York
Regeneron Research Facility, New York
Montefiore Hospital, The Bronx
Regeneron Research Facility, Nyack
New York Cancer and Blood Specialists, Port Jefferson Station
Roswell Park Cancer Institute, Buffalo
St. Luke's University Health Network, Bethlehem
Baltimore Veterans Affairs Medical Center, Baltimore
Frederick Health, Frederick
Inova Schar Cancer Institute, Fairfax
University of Virginia, Charlottesville
Durham VA Medical Center, Durham
Oncology Specialists of Charlotte, PA, Charlotte
Clinical Research Center of the Carolinas, Charleston
Charleston Hematology Oncology Associates, PA, Charleston
Lewis Hall Singletary Oncology Center at John D. Archbold Memorial Hospital, Thomasville
Mayo Clinic, Jacksonville
Regeneron Research Facility, Miami
Miami Cancer Institute at Baptist Health, Inc., Miami
Moffitt Cancer Center, Tampa
Integrity Clinical Research, Delray Beach
Regeneron Research Facility, Largo
Oncology Specialties, PC - Clearview Cancer Institute, Huntsville
University of Tennessee Medical Center, Knoxville
Reid Oncology Association, Richmond
University of Michigan, Ann Arbor
NorthShore University HealthSystem, Evanston
Northwestern University, Chicago
Southeast Nebraska Hematology & Oncology Consultants, PC, Lincoln
CHRISTUS Highland Cancer Treatment Center, Shreveport
CARTI Cancer Center, Little Rock
Texas Oncology, Dallas
University of Texas Southwestern, Dallas
MD Anderson Cancer Center, Houston
Renovatio Clinical, The Woodlands
Texas Oncology-Amarillo Cancer Center, Amarillo
University of Colorado, Aurora
The Melanoma and Skin Cancer Institute, Englewood
Dignity Health St. Joseph's Hospital and Medical Center, Phoenix
Optum Cancer Care, Las Vegas
Harbor-UCLA/LA Biomedical Research Institute, Los Angeles
University of California San Diego, La Jolla
Regeneron Research Facility, Stanford
St. Mary's Medical Center, San Francisco
Oregon Health & Science University, Portland
Asante Rogue Regional Medical Center, Medford
Regional Cancer Care Associates, LLC, Manchester
Dana-Farber Cancer Institute, Boston
Lahey Hospital & Medical Center, Burlington
Regeneron Research Facility, Elizabeth
University of Vermont, Burlington
Pan-American Center for Oncology Trials, LLC, Rio Piedras
FDI Clinical Research, San Juan
Regeneron Pharmaceuticals
INDUSTRY